Postprandial glycaemic dips predict appetite and energy intake in healthy individuals.

"Conflict of interest statement: TD Spector, SE Berry, AM Valdes, PW Franks, A Chan are consultants to Zoe Global Ltd (“Zoe”). J Wolf, G Hadjigeorgiou, H Al Khatib, P Wyatt and I Linenberg are or have been employees of Zoe. JE Blundell is a member of Zoe Global scientific Advisory Board. Other authors have no conflict of interest to declare."

"We express our sincere thanks to the participants of the PREDICT 1 study. We thank the staff of Zoe Global, the Department of Twin Research and Massachusetts General Hospital for their tireless work in contributing to the running of the study and data collection. We thank Abbott for their support with using their CGMs. This work was supported by Zoe Global Ltd also received support from grants from the Wellcome Trust (212904/Z/18/Z) and the Medical Research Council (MRC)/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension (AIMHY; MR/M016560/1). PWF was supported in part by grants from the European Research Council (CoG-2015_681742_NASCENT), Swedish Research Council, Novo Nordisk Foundation and the Swedish Foundation for Strategic Research (IRC award). AMV was supported by the National Institute for Health Research Nottingham Biomedical Research Centre. TwinsUK is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London."

"The PREDICT 1 Cohort 1 study() (Personalised REsponses to DIetary Composition Trial) was a two-centre study conducted between 2018 and 2019. The first participant was enrolled on 4 August 2018, the last clinical visit was completed on 24 April 2019, with the primary cohort based at King’s College London, UK, and a validation cohort (that underwent the same profiling as in the UK) assessed at Massachusetts General Hospital (MGH) in Boston, Massachusetts, USA. In the UK, participants (target enrolment = 1,000, total enrolled n=1010) were recruited from the TwinsUK cohort, a prospective cohort study and online advertising. In the US, participants (target enrolment = 100, total enrolled = 100) were recruited through online advertising, research participant databases and Rally for Research (https://rally.partners.org/), an online recruiting portal for research trials. Ethical approvals for the studies were obtained in the UK Ethics was granted by the London - Hampstead Research Ethics Committee (REC approval18/LO/0663) Research Ethics Committee and Integrated Research Application System (IRAS 236407) and by the Partners Healthcare Institutional Review Board (IRB 2018P002078). The informed consent and ethical committee approvals covered all analysis reported in the current study in addition to the key primary outcomes described in Berry et al (). The trial is registered at ClinicalTrials.gov (registration number: NCT03479866) and was run in accordance with the Declaration of Helsinki and Good Clinical Practice. Descriptive characteristics of participants included in this substudy are shown in ."